-
EP3233900
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3233900
| EP3233900 - CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 03.04.2018 Database last updated on 03.09.2024 | |
| Former | Request for examination was made Status updated on 22.09.2017 | ||
| Former | The international publication has been made Status updated on 21.07.2017 | Most recent event Tooltip | 27.12.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US | [2017/43] | Inventor(s) | 01 /
MARASCO, Wayne, A. 43 Rice Street Wellesley, MA 02481 / US | [2017/43] | Representative(s) | Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB | [N/P] |
| Former [2017/43] | Cooley (UK) LLP Dashwood 69 Old Broad Street London EC2M 1QS / GB | Application number, filing date | 15828615.3 | 21.12.2015 | [2017/43] | WO2015US67225 | Priority number, date | US201462094625P | 19.12.2014 Original published format: US 201462094625 P | US201562252083P | 06.11.2015 Original published format: US 201562252083 P | [2017/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2016100985 | Date: | 23.06.2016 | Language: | EN | [2016/25] | Type: | A2 Application without search report | No.: | EP3233900 | Date: | 25.10.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.06.2016 takes the place of the publication of the European patent application. | [2017/43] | Search report(s) | International search report - published on: | EP | 18.08.2016 | Classification | IPC: | C07K14/705, C07K19/00, C07K14/735, C07K14/725 | [2017/43] | CPC: |
C07K14/7051 (EP,IL,KR,US);
C07K14/705 (EP,IL,KR,US);
C07K14/70521 (EP,IL,KR,US);
C07K14/70535 (EP,IL,KR,US);
C07K14/70578 (EP,IL,KR,US);
C07K16/2827 (IL,KR);
C07K19/00 (IL,US);
C07K2317/622 (IL,KR);
C07K2319/02 (EP,IL,KR,US);
C07K2319/03 (EP,IL,KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/43] | Title | German: | CHIMÄRE ANTIGEN-REZEPTOREN UND VERFAHREN ZUR VERWENDUNG DAVON | [2017/43] | English: | CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF | [2017/43] | French: | RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES ET LEURS PROCÉDÉS D'UTILISATION | [2017/43] | Entry into regional phase | 19.07.2017 | National basic fee paid | 19.07.2017 | Designation fee(s) paid | 19.07.2017 | Examination fee paid | Examination procedure | 19.07.2017 | Examination requested [2017/43] | 19.07.2017 | Date on which the examining division has become responsible | 16.02.2018 | Amendment by applicant (claims and/or description) | 06.04.2018 | Despatch of a communication from the examining division (Time limit: M06) | 15.10.2018 | Reply to a communication from the examining division | 07.12.2018 | Despatch of a communication from the examining division (Time limit: M06) | 23.05.2019 | Reply to a communication from the examining division | 19.09.2019 | Despatch of a communication from the examining division (Time limit: M04) | 28.01.2020 | Reply to a communication from the examining division | 12.03.2020 | Observations by third parties | 19.05.2020 | Despatch of a communication from the examining division (Time limit: M04) | 15.09.2020 | Reply to a communication from the examining division | 12.01.2021 | Despatch of a communication from the examining division (Time limit: M06) | 12.08.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 21.10.2021 | Reply to a communication from the examining division | 03.05.2023 | Despatch of a communication from the examining division (Time limit: M06) | 13.11.2023 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 21.10.2021 | Request for further processing filed | 21.10.2021 | Full payment received (date of receipt of payment) Request granted | 02.11.2021 | Decision despatched | Fees paid | Renewal fee | 27.12.2017 | Renewal fee patent year 03 | 31.12.2018 | Renewal fee patent year 04 | 27.12.2019 | Renewal fee patent year 05 | 29.03.2021 | Renewal fee patent year 06 | 27.12.2021 | Renewal fee patent year 07 | 27.12.2022 | Renewal fee patent year 08 | 27.12.2023 | Renewal fee patent year 09 | Penalty fee | Additional fee for renewal fee | 31.12.2020 | 06 M06 Fee paid on 29.03.2021 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2005044996 (ST JUDE CHILDRENS RES HOSPITAL [US], et al) [A] 1-19 * the whole document *; | [XI]WO2013154760 (US HEALTH [US]) [X] 1-18 * Whole document, especially the claims * [I] 19; | [XAI]WO2014011988 (UNIV PENNSYLVANIA [US]) [X] 1-8,10-12,14-18 * Whole document, especially the claims 23-27, 29,31,33 * [A] 20,21 [I] 19; | [XI] - CARPENTER R O ET AL, "B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 19, no. 8, doi:10.1158/1078-0432.CCR-12-2422, ISSN 1078-0432, (20130415), pages 2048 - 2060, (20130123), XP002727959 [X] 1-18 * Whole document especially page 2050, left column §2 * [I] 19 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-12-2422 | [XI] - XIAO-SONG ZHONG ET AL, "Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication", MOLECULAR THERAPY, (20100201), vol. 18, no. 2, doi:10.1038/mt.2009.210, ISSN 1525-0016, pages 413 - 420, XP055023623 [X] 1-8,10-12,14-18,20 * Whole document, especially figure 1a * [I] 19 DOI: http://dx.doi.org/10.1038/mt.2009.210 | [A] - M. SADELAIN ET AL, "The Basic Principles of Chimeric Antigen Receptor Design", CANCER DISCOVERY, (20130401), vol. 3, no. 4, doi:10.1158/2159-8290.CD-12-0548, ISSN 2159-8274, pages 388 - 398, XP055133523 [A] 1-19 * the whole document * DOI: http://dx.doi.org/10.1158/2159-8290.CD-12-0548 | [A] - JULIE R BRAHMER ET AL, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, (20120628), vol. 366, no. 26, doi:10.1056/NEJMOA1200694, ISSN 1533-4406, pages 2455 - 2465, XP002685330 [A] 21 * abstract * DOI: http://dx.doi.org/10.1056/NEJMoa1200694 | [XP] - Wayne A Marasco ET AL, "Carbonic Anhydrdase IX: Opportunities for Immune-Based Approaches", (20151107), URL: http://www.euikcs.com/kca/miami/docs/h6-marasco.pdf, (20160411), XP055264162 [XP] 1-21 * the whole document * | by applicant | US5994136 | US6013516 | - THOMAS; CAPECCHI, CELL, (1987), vol. 51, pages 503 - 512 | - MANSOUR ET AL., NATURE, (1988), vol. 336, pages 348 - 352 | - JOYNER ET AL., NATURE, (1989), vol. 338, pages 153 - 156 | - IVANOV S; LIAO SY; IVANOVA A ET AL., "Danilkovitch-Miagkova A, Tarasova N, Weirich G et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer", AM JPATHOL, (2001), vol. 158, no. 3, pages 905 - 19 | - LONCASTER JA; HARRIS AL; DAVIDSON SE; LOGUE JP; HUNTER RD; WYCOFF CC ET AL., "Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix", CANCER RESEARCH, (2001), vol. 61, no. 17, pages 6394 - 9 | - HILVO M; BARANAUSKIENE L; SALZANO AM; SCALONI A; MATULIS D; INNOCENTI A ET AL., "Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes", JBIOL CHEM, (2008), vol. 283, no. 41, pages 27799 - 809 | - OOSTERWIJK E; RUITER DJ; HOEDEMAEKER PJ; PAUWELS EK; JONAS U; ZWARTENDIJK J ET AL., "Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER, (1986), vol. 38, no. 4, doi:doi:10.1002/ijc.2910380406, pages 489 - 94, XP008009792 DOI: http://dx.doi.org/10.1002/ijc.2910380406 | - LIAO SY; BREWER C; ZAVADA J; PASTOREK J; PASTOREKOVA S; MANETTA A ET AL., "Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas", AM JPATHOL, (1994), vol. 145, no. 3, pages 598 - 609, XP002933894 | - LIAO SY; AURELIO ON; JAN K; ZAVADA J; STANBRIDGE EJ., "Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney", CANCER RESEARCH, (1997), vol. 57, no. 14, pages 2827 - 2831 | - ATKINS M; REGAN M; MCDERMOTT D; MIER J; STANBRIDGE E; YOUMANS A ET AL., "Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer", CLIN CANCER RES, (2005), vol. 11, no. 10, pages 3714 - 3721 | - LOKICH J., "Spontaneous regression of metastatic renal cancer. Case report and literature review", AM J CLIN ONCOL, (1997), vol. 20, no. 4, pages 416 - 418 | - CHANG AE; LI Q; JIANG G; SAYRE DM; BRAUN TM; REDMAN BG., "Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer", J CLIN ONCOL, (2003), vol. 21, no. 5, pages 884 - 890 | - DUDLEY ME; WUNDERLICH JR; ROBBINS PF; YANG JC; HWU P; SCHWARTZENTRUBER DJ ET AL., "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.", SCIENCE, (2002), vol. 298, no. 5594, doi:doi:10.1126/science.1076514, pages 850 - 854, XP009113075 DOI: http://dx.doi.org/10.1126/science.1076514 | - SCHAFT N; WILLEMSEN RA; DE VRIES J; LANKIEWICZ B; ESSERS BW; GRATAMA JW ET AL., "Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes", J IMMUNOL, (2003), vol. 170, no. 4, pages 2186 - 2194 | - BUBENIK J., "MHC class I down-regulation: tumour escape from immune surveillance? (review", INTERNATIONAL JOURNAL OF ONCOLOGY, (2004), vol. 25, no. 2, pages 487 - 491 | - GAJEWSKI TF; MENG Y; BLANK C; BROWN I; KACHA A; KLINE J ET AL., "Immune resistance orchestrated by the tumor microenvironment.", IMMUNOLOGICAL REVIEWS, (2006), vol. 213, pages 131 - 145 | - FRIGOLA X; INMAN BA; LOHSE CM; KRCO CJ; CHEVILLE JC; THOMPSON RH ET AL., "Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma", CLIN CANCER RES, (2011), vol. 17, no. 7, pages 1915 - 1923 | - GREPIN R; GUYOT M; GIULIANO S; BONCOMPAGNI M; AMBROSETTI D; CHAMOREY E ET AL., "The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.", CANCER RESEARCH, (2014), vol. 74, no. 3, doi:doi:10.1158/0008-5472.CAN-13-1267, pages 873 - 883, XP055371270 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-13-1267 | - SADELAIN M; BRENTJENS R; RIVIERE I., "The promise and potential pitfalls of chimeric antigen receptors", CURR OPIN IMMUNOL, (2009), vol. 21, no. 2, doi:doi:10.1016/j.coi.2009.02.009, pages 215 - 223, XP026058399 DOI: http://dx.doi.org/10.1016/j.coi.2009.02.009 | - LAMERS CH; SLEIJFER S; VAN STEENBERGEN S; VAN ELZAKKER P; VAN KRIMPEN B; GROOT C ET AL., "Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, (2013), vol. 21, no. 4, pages 904 - 912, XP002755666 | - MILONE MC; FISH JD; CARPENITO C; CARROLL RG; BINDER GK; TEACHEY D ET AL., "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, (2009), vol. 17, no. 8, pages 1453 - 1464 | - WILKIE S; PICCO G; FOSTER J; DAVIES DM; JULIEN S; COOPER L ET AL., "Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor", J IMMUNOL, (2008), vol. 180, no. 7, pages 4901 - 4909 | - LO AS; MA Q; LIU DL; JUNGHANS RP., "Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors", CLIN CANCER RES, (2010), vol. 16, no. 10, doi:doi:10.1158/1078-0432.CCR-10-0043, pages 2769 - 2780, XP002754564 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-10-0043 | - KALOS M; LEVINE BL; PORTER DL; KATZ S; GRUPP SA; BAGG A ET AL., "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia", SCIENCE TRANSLATIONAL MEDICINE, (2011), vol. 3, no. 95, doi:doi:10.1126/scitranslmed.3002842, page 95RA73, XP002667262 DOI: http://dx.doi.org/10.1126/scitranslmed.3002842 | - PEGRAM HJ; PARK JH; BRENTJENS RJ., "CD28z CARs and armored CARs", CANCER J, (2014), vol. 20, no. 2, doi:doi:10.1097/PPO.0000000000000034, pages 127 - 133, XP055247596 DOI: http://dx.doi.org/10.1097/PPO.0000000000000034 | - XU C; LO A; YAMMANURU A; TALLARICO AS; BRADY K; MURAKAMI A ET AL., "Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology", PLOS ONE, (2010), vol. 5, no. 3, page E9625 | - SUI J; AIRD DR; TAMIN A; MURAKAMI A; YAN M; YAMMANURU A ET AL., "Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway", PLOSPATHOGENS, (2008), vol. 4, no. 11, doi:doi:10.1371/JOURNAL.PPAT.1000197, page E1000197, XP003029224 DOI: http://dx.doi.org/10.1371/JOURNAL.PPAT.1000197 | - MIRZABEKOV T; KONTOS H; FARZAN M; MARASCO W; SODROSKI J., "Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5.", NAT BIOTECHNOL, (2000), vol. 18, no. 6, doi:doi:10.1038/76501, pages 649 - 654, XP002952021 DOI: http://dx.doi.org/10.1038/76501 | - WALD O; WEISS ID; WALD H; SHOHAM H; BAR-SHAVIT Y; BEIDER K ET AL., "IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs", JIMMUNOL, (2006), vol. 176, no. 8, pages 4716 - 4729 | - ZEYTIN H; REALI E; ZAHAROFF DA; ROGERS CJ; SCHLOM J; GREINER JW., "Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity", JOURNAL OF INTERFERON & CYTOKINE RESEARCH : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR INTERFERON AND CYTOKINE RESEARCH, (2008), vol. 28, no. 2, pages 73 - 87 | - MURUGAIYAN G; SAHA B., "Protumor vs antitumor functions of IL-17", JIMMUNOL, (2009), vol. 183, no. 7, pages 4169 - 4175 | - BAR E; WHITNEY PG; MOOR K; REIS E SOUSA C, "LeibundGut-Landmann S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells", IMMUNITY, (2014), vol. 40, no. 1, pages 117 - 127 | - HINRICHS CS; KAISER A; PAULOS CM; CASSARD L; SANCHEZ-PEREZ L; HEEMSKERK B ET AL., "Type 17 CD8+ T cells display enhanced antitumor immunity", BLOOD, (2009), vol. 114, no. 3, pages 596 - 599 | - HOMBACH AA; RAPPL G; ABKEN H., "Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 ''super-stimulation", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, (2013), vol. 21, no. 12, pages 2268 - 2277 | - MOR F; COHEN IR., "IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2", J IMMUNOL, (1996), vol. 156, no. 2, pages 515 - 522 | - ISAKOV N; ALTMAN A., "PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors", FRONTIERS IN IMMUNOLOGY, (2012), vol. 3, page 273 | - LOSKOG A; GIANDOMENICO V; ROSSIG C; PULE M; DOTTI G; BRENNER MK., "Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells", LEUKEMIA, (2006), vol. 20, no. 10, doi:doi:10.1038/sj.leu.2404366, pages 1819 - 1828, XP055109421 DOI: http://dx.doi.org/10.1038/sj.leu.2404366 | - SCHWARZER A; WOLF B; FISHER JL; SCHWAAB T; OLEK S; BARON U ET AL., "Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy", PLOS ONE, (2012), vol. 7, no. 10, page E46600 | - LAMERS CH; WILLEMSEN R; VAN ELZAKKER P; VAN STEENBERGEN-LANGEVELD S; BROERTJES M; OOSTERWIJK-WAKKA J ET AL., "Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells", BLOOD, (2011), vol. 117, no. 1, doi:doi:10.1182/blood-2010-07-294520, pages 72 - 82, XP055234814 DOI: http://dx.doi.org/10.1182/blood-2010-07-294520 | - MIOTTI S; NEGRI DR; VALOTA O; CALABRESE M; BOLHUIS RL; GRATAMA JW ET AL., "Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER, (1999), vol. 84, no. 1, pages 62 - 68 | - KERSHAW MH; WESTWOOD JA; PARKER LL; WANG G; ESHHAR Z; MAVROUKAKIS SA ET AL., "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer", CLIN CANCER RES, (2006), vol. 12, pages 6106 - 15 | - PASTOREKOVA S., "Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy", CANCER THERAPY, (2004), vol. 2, pages 245 - 262 | - PASTOREKOVA S; PARKKILA S; PARKKILA AK; OPAVSKY R; ZELNIK V; SAARNIO J ET AL., "Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts", GASTROENTEROLOGY, (1997), vol. 112, no. 2, doi:doi:10.1053/gast.1997.v112.pm9024293, pages 398 - 408, XP000909802 DOI: http://dx.doi.org/10.1053/gast.1997.v112.pm9024293 | - SAAMIO J; PARKKILA S; PARKKILA AK; WAHEED A; CASEY MC; ZHOU XY ET AL., "Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity", THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY : OFFICIAL JOURNAL OF THE HISTOCHEMISTRY SOCIETY, (1998), vol. 46, no. 4, pages 497 - 504 | - ZAVADA J; ZAVADOVA Z; ZAT'OVICOVA M; HYRSL L; KAWACIUK I., "Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients", BR J CANCER, (2003), vol. 89, no. 6, doi:doi:10.1038/SJ.BJC.6601264, pages 1067 - 71, XP002693545 DOI: http://dx.doi.org/10.1038/SJ.BJC.6601264 | - HOMBACH A; KOCH D; SIRCAR R; HEUSER C; DIEHL V; KRUIS W ET AL., "A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA", GENE THER, (1999), vol. 6, no. 2, pages 300 - 4 | - CARPENITO C; MILONE MC; HASSAN R; SIMONET JC; LAKHAL M; SUHOSKI MM ET AL., "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OFAMERICA, (2009), vol. 106, no. 9, doi:doi:10.1073/pnas.0813101106, pages 3360 - 5, XP002732434 DOI: http://dx.doi.org/10.1073/pnas.0813101106 | - HOMBACH AA; HEIDERS J; FOPPE M; CHMIELEWSKI M; ABKEN H., "OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells", ONCOIMMUNOLOGY, (2012), vol. 1, no. 4, doi:doi:10.4161/onci.19855, pages 458 - 466, XP055403337 DOI: http://dx.doi.org/10.4161/onci.19855 | - SONG DG; YE Q; CARPENITO C; POUSSIN M; WANG LP; JI C ET AL., "In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB", CANCER RESEARCH, (2011), vol. 71, no. 13, doi:doi:10.1158/0008-5472.CAN-11-0422, pages 4617 - 27, XP055526216 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-11-0422 | - BEDKE J; STENZL A., "Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?", EXPERT REVIEW OF ANTICANCER THERAPY, (2013), vol. 13, no. 12, pages 1399 - 408 | - BAILEY A; MCDERMOTT DF., "Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics", CANCER J, (2013), vol. 19, no. 4, pages 348 - 52 | - MAHER J; BRENTJENS RJ; GUNSET G; RIVIERE I; SADELAIN M., "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor", NAT BIOTECHNOL, (2002), vol. 20, no. 1, pages 70 - 5, XP002588277 | - FERLAY J; SOERJOMATARAM I; DIKSHIT R; ESER S; MATHERS C; REBELO M ET AL., "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", INTERNATIONAL JOURNAL OF CANCER, (2015), vol. 136, pages E359 - 86 | - DUTCHER JP., "Recent developments in the treatment of renal cell carcinoma", THERAPEUTIC ADVANCES IN UROLOGY, (2013), vol. 5, pages 338 - 53 | - COHEN HT; MCGOVERN FJ., "Renal-cell carcinoma", THE NEW ENGLAND JOURNAL OF MEDICINE, (2005), vol. 353, pages 2477 - 90 | - SEDLAKOVA O; SVASTOVA E; TAKACOVA M; KOPACEK J; PASTOREK J; PASTOREKOVA S., "Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors", FRONTIERS IN PHYSIOLOGY, (2014), vol. 4, page 400 | - BENEJ M; PASTOREKOVA S; PASTOREK J., "Carbonic anhydrase IX: regulation and role in cancer", SUB-CELLULAR BIOCHEMISTRY, (2014), vol. 75, pages 199 - 219 | - TOSTAIN J; LI G; GENTIL-PERRET A; GIGANTE M., "Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment", EUROPEAN JOURNAL OF CANCER., (2010), vol. 46, pages 3141 - 8 | - GENEGA EM; GHEBREMICHAEL M; NAJARIAN R; FU Y; WANG Y; ARGANI P ET AL., "Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, (2010), vol. 134, doi:doi:10.1309/AJCPPPR57HNJMSLZ, pages 873 - 9, XP055110184 DOI: http://dx.doi.org/10.1309/AJCPPPR57HNJMSLZ | - ALEGRE ML; FRAUWIRTH KA; THOMPSON CB., "T-cell regulation by CD28 and CTLA-4", NATURE REVIEWS IMMUNOLOGY, (2001), vol. 1, doi:doi:10.1038/35105024, pages 220 - 8, XP055345954 DOI: http://dx.doi.org/10.1038/35105024 | - PARDOLL DM., "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS CANCER, (2012), vol. 12, doi:doi:10.1038/nrc3239, pages 252 - 64, XP055415943 DOI: http://dx.doi.org/10.1038/nrc3239 | - HARSHMAN LC; DRAKE CG; CHOUEIRI TK., "PD-1 blockade in renal cell carcinoma: to equilibrium and beyond", CANCER IMMUNOLOGY RESEARCH, (2014), vol. 2, doi:doi:10.1158/2326-6066.CIR-14-0193, pages 1132 - 41, XP055275769 DOI: http://dx.doi.org/10.1158/2326-6066.CIR-14-0193 | - SRIVASTAVA S; RIDDELL SR., "Engineering CAR-T cells: Design concepts", TRENDS IN IMMUNOLOGY, (2015), vol. 36, doi:doi:10.1016/j.it.2015.06.004, pages 494 - 502, XP055251965 DOI: http://dx.doi.org/10.1016/j.it.2015.06.004 | - MAUDE SL; FREY N; SHAW PA; APLENC R; BARRETT DM; BUNIN NJ ET AL., "Chimeric antigen receptor T cells for sustained remissions in leukemia", THE NEW ENGLAND JOURNAL OF MEDICINE, (2014), vol. 371, doi:doi:10.1056/NEJMoa1407222, pages 1507 - 17, XP055188099 DOI: http://dx.doi.org/10.1056/NEJMoa1407222 | - KAKARLA S; GOTTSCHALK S., "CAR T cells for solid tumors: armed and ready to go?", CANCER JOURNAL, (2014), vol. 20, pages 151 - 5 | - LO AS; XU C; MURAKAMI A; MARASCO WA., "Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T-cells expressing a human anti-CAIX chimeric antigen receptor", MOLECULAR THERAPY - ONCOLYTICS, (2014), vol. 1, pages 1 - 12 | - HSU CY; ULUDAG H., "A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine", NATURE PROTOCOLS, (2012), vol. 7, pages 935 - 45 | - SINGH H; FIGLIOLA MJ; DAWSON MJ; HULS H; OLIVARES S; SWITZER K ET AL., "Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies", CANCER RESEARCH, (2011), vol. 71, doi:doi:10.1158/0008-5472.CAN-10-3843, pages 3516 - 27, XP055295461 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-10-3843 | - JUNE C; ROSENBERG SA; SADELAIN M; WEBER JS., "T-cell therapy at the threshold", NATURE BIOTECHNOLOGY, (2012), vol. 30, pages 611 - 4 | - CHANG DK; MONIZ RJ; XU Z; SUN J; SIGNORETTI S; ZHU Q ET AL., "Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo", MOLECULAR CANCER., (2015), vol. 14, page 119 | - KAKA AS; SHAFFER DR; HARTMAIER R; LEEN AM; LU A; BEAR A ET AL., "Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes", JOURNAL OF IMMUNOTHERAPY, (2009), vol. 32, pages 726 - 36 | - LI Y; BLEAKLEY M; YEE C., "IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response", JOURNAL OF IMMUNOLOGY, (2005), vol. 175, pages 2261 - 9, XP002389121 | - VAN DER STEGEN SJ; HAMIEH M; SADELAIN M., "The pharmacology of second-generation chimeric antigen receptors", NATURE REVIEWS DRUG DISCOVERY, (2015), vol. 14, doi:doi:10.1038/nrd4597, pages 499 - 509, XP055276028 DOI: http://dx.doi.org/10.1038/nrd4597 | - LONG AH; HASO WM; SHEM JF; WANHAINEN KM; MURGAI M; INGARAMO M ET AL., "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", NATURE MEDICINE, (2015), vol. 21, doi:doi:10.1038/nm.3838, pages 581 - 90, XP055278553 DOI: http://dx.doi.org/10.1038/nm.3838 | - LEE DW; KOCHENDERFER JN; STETLER-STEVENSON M; CUI YK; DELBROOK C; FELDMAN SA ET AL., "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial", LANCET, (2015), vol. 385, doi:doi:10.1016/S0140-6736(14)61403-3, pages 517 - 28, XP055388598 DOI: http://dx.doi.org/10.1016/S0140-6736(14)61403-3 | - VIRGIN HW; WHERRY EJ; AHMED R., "Redefining chronic viral infection", CELL, (2009), vol. 138, pages 30 - 50 | - WHERRY EJ., "T cell exhaustion", NATURE IMMUNOLOGY, (2011), vol. 12, doi:doi:10.1038/ni.2035, pages 492 - 9, XP055445573 DOI: http://dx.doi.org/10.1038/ni.2035 | - TOPALIAN SL; HODI FS; BRAHMER JR; GETTINGER SN; SMITH DC; MCDERMOTT DF ET AL., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, (2012), vol. 366, doi:doi:10.1056/NEJMoa1200690, pages 2443 - 54, XP055098235 DOI: http://dx.doi.org/10.1056/NEJMoa1200690 | - BRAHMER JR; TYKODI SS; CHOW LQ; HWU WJ; TOPALIAN SL; HWU P ET AL., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, (2012), vol. 366, doi:doi:10.1056/NEJMoa1200694, pages 2455 - 65, XP002685330 DOI: http://dx.doi.org/10.1056/NEJMoa1200694 | - JOHN LB; DEVAUD C; DUONG CP; YONG CS; BEAVIS PA; HAYNES NM ET AL., "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, (2013), vol. 19, doi:doi:10.1158/1078-0432.CCR-13-0458, pages 5636 - 46, XP002737460 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-13-0458 |